SCHEDULE: State Street Discloses 6.4% Stake in Myriad Genetics
Beneficial Ownership Report
State Street Corporation has reported a 6.4% beneficial ownership stake in Myriad Genetics Inc. common stock as of December 31, 2025.
Summary
- State Street Corporation, a Massachusetts-based parent holding company, has filed a Schedule 13G indicating beneficial ownership in Myriad Genetics Inc.
- As of December 31, 2025, State Street Corporation beneficially owned 5,966,567 shares of Myriad Genetics' common stock.
- This ownership represents 6.4% of the total class of securities.
- State Street Corporation holds shared voting power over 5,683,556 shares and shared dispositive power over all 5,966,567 shares.
- The securities were acquired and are held in the ordinary course of business, not for the purpose of changing or influencing control of Myriad Genetics Inc.
Sentiment
Score: 6
Explanation: StockSavvy.ai views this as a neutral to slightly positive disclosure. While a 13G is a standard regulatory filing, the disclosure of a significant institutional stake by a major asset manager like State Street can be interpreted as a vote of confidence in the issuer, Myriad Genetics.
Future Outlook
NA
Industry Context
StockSavvy.ai notes that Schedule 13G filings are routine disclosures by institutional investors, such as State Street Corporation, when they acquire more than 5% of a company's voting class of securities, but do not intend to influence or control the company. This filing indicates continued institutional interest in Myriad Genetics, a company operating in the genetic testing and precision medicine sector.
Stakeholder Impact
- Shareholders: The disclosure of a significant institutional stake by State Street Corporation may provide a level of confidence and stability, potentially attracting further institutional investment.
- Company Management: Awareness of a large institutional holder may influence strategic decisions, though State Street has certified it does not intend to influence control.
Key Dates
| Date | Description |
|---|---|
| 12/31/2025 | Date of event which requires the filing of this statement, indicating the beneficial ownership position as of the end of the calendar year. |
| 02/09/2026 | Date the Schedule 13G statement was signed by State Street Corporation. |
Keywords
Myriad Genetics, State Street Corporation, Beneficial Ownership, Schedule 13G, Institutional Investor, Common Stock, Healthcare, Biotechnology
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.